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Rapid and accurate detection of multidrug resistance (MDR) inMycobacterium tuberculosis is essential to improve treatment
outcomes and reduce global transmission but remains a challenge. Rifampin (RIF) resistance is a reliable marker of MDR tuber-
culosis (TB) since by far the majority of RIF-resistant strains are also isoniazid (INH) resistant. We have developed a rapid, sen-
sitive, and specific method for detecting the most commonmutations associated with RIF resistance, in the RIF resistance deter-
mining region (RRDR) of rpoB, using a cocktail of six padlock probes and rolling circle amplification (RCA). We used this
method to test 46 storedM. tuberculosis clinical isolates with known RIF susceptibility profiles (18 RIF resistant, 28 susceptible),
a standard susceptible strain (H37Rv, ATCC 27294) and 78M. tuberculosis culture-positive clinical (sputum) samples, 59 of
which grew RIF-resistant strains. All stored clinical isolates were correctly categorized, by the padlock probe/RCAmethod, as
RIF susceptible or resistant; the sensitivity and specificity of the method, for direct detection of phenotypically RIF-resistantM.
tuberculosis in clinical specimens, were 96.6 and 89.5%, respectively. This method is rapid, simple, and inexpensive and has the
potential for high-throughput routine screening of clinical specimens for MDRM. tuberculosis, particularly in high prevalence
settings with limited resources.
With one-third of the world’s population infected, tuberculo-sis (TB) is a major public health threat worldwide (1). The
two most important drugs used to treat TB are isoniazid (INH)
and rifampin (RIF). Inadequate or inappropriate therapy, to-
gether with long and costly treatment courses, often result in the
emergence of drug resistance (2). Multidrug-resistant (MDR)
Mycobacterium tuberculosis strains— defined as bacillary resis-
tance to at least INH and RIF— have spread rapidly and become a
global health emergency (3). Identification of these strains by drug
susceptibility testing (DST) allows optimization of therapeutic ef-
ficacy and improved treatment outcomes while minimizing trans-
mission of drug-resistant strains. However, phenotypic DST in-
volving subculture is costly, it is too slow to guide optimal
management of MDR-TB, and it lacks high-throughput capabil-
ity. Commercial systems for rapid molecular identification of RIF
resistance are available but expensive.
RIF resistance in M. tuberculosis is associated with amino acid
changes in the -subunit of RNA polymerase, encoded by rpoB.
The majority (90 to 95%) of mutations responsible for resis-
tance are located in the 81-bp RIF resistance determining re-
gion (RRDR) of rpoB (4–6), and ca. 60 to 70% are found within
two codons, 531 and 526. The fact that most mutations known
to confer resistance are localized to a specific region facilitates
the development of molecular methods for their detection. Se-
quencing and hybridization-based assays have been commonly
used and can define the precise mutations involved (4, 7).
Hybridization-based assays also provide a rapid and high-
throughput approach (8).
Recent studies have shown that the use of padlock probes offers
advantages over other techniques for detection of genetic muta-
tions, including single-nucleotide polymorphisms (SNPs); liga-
tion of the probe ends by DNA ligase requires perfectly matched
target-probe complexes, which prevents the nonspecific amplifi-
cation that can occur with conventional PCR and results in very
high specificity (9). A padlock probe comprises two sequences
complementary to the 5= and 3= termini of the target sequence,
joined by a genetic linker region. When they hybridize, head to
tail, with the target, the 5= and 3= ends of the probe are juxtaposed,
forming a closed, circular molecule after incubation with a DNA
ligase. The ability of padlock probes to accurately identify SNPs
has been demonstrated (10, 11), and the intensity of the signal
generated by the circularized probe can be increased, exponen-
tially, by rolling circle amplification (RCA) (12).
In the present study, we developed a RCA assay using six pad-
lock probes to recognize 12 common resistance-associated muta-
tions in the RRDR of rpoB of M. tuberculosis. Our choice of tar-
geted mutations was based on analysis of mutations in the RRDR
of 242M. tuberculosis isolates, by Huang et al. (13). They identified
60 different mutations in RIF-resistant isolates, of which those, at
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codons 511, 516, 526 and 531, accounted for almost 90% of all
mutations identified. Others (14–17) have reported similar re-
sults. After validating its sensitivity and specificity, we used the
assay to examine RIF resistance in M. tuberculosis isolates and
sputum specimens from patients with active tuberculosis. Its di-
agnostic accuracy was compared to the standard rpoB PCR/se-
quencing and phenotypic DST.
MATERIALS AND METHODS
Clinical isolates. A total of 46 stored M. tuberculosis clinical isolates were
chosen for the present study, including five RIF-resistant from the New
South Wales Mycobacterium Reference Laboratory, Centre for Infectious
Diseases and Microbiology, Westmead Hospital, and 13 RIF-resistant and
28 RIF-susceptible isolates from Department of Tuberculosis, Beijing
Chest Hospital, Capital Medical University, China. In addition, a stan-
dard susceptible strain, H37Rv (ATCC 27294), was included as control.
Isolates were stored in 1% glycerol or 7H9 broth (without oleic acid-
albumin-dextrose-catalase [OADC]) at80°C until required, when they
were thawed and subcultured on Lowenstein-Jensen (L-J) agar slants for 3
to 4 weeks at 35 to 37°C in air.
Clinical sputum samples: collection and processing. A total of 78
nonduplicate sputum specimens were collected between May and Decem-
ber 2012 from pulmonary TB patients admitted to the Beijing Chest Hos-
pital, Capital Medical University, Beijing, China. The diagnosis of pulmo-
nary TB was based on clinical and radiological findings, together with
identification of acid-fast bacilli (AFB) in sputum and subsequent isola-
tion of M. tuberculosis in culture. All patients were HIV seronegative, and
written informed consent for additional testing of specimens was ob-
tained from all patients involved in the study.
Early morning sputum specimens were digested and decontaminated
with N-acetyl-L-cysteine-sodium hydroxide (NALC-NaOH). Specimens
in which AFBs were identified by microscopy were split into two aliquots.
One aliquot was use for molecular testing (see below), and the other was
processed for standard culture on L-J slants, followed by strain identifica-
TABLE 1 RCA padlock probes and primers designed for this study
Padlock probe/primers Sequence (5=–3=)a
Probe-rpoB-511-C-C/G-C P-GCTGGCTGGTGCCGAAGATCATGCTTCTTCGGTGCCCATAATGCCACGTTAACAGTCAGCGCGCAGACA
CGATAGTCTAGGTCCATGAATTGGCTCS
Probe-rpoB-514-TTCTTC P-GAATTGGCTCAGCTGGCTGGGATCATGCTTCTTCGGTGCCCATTGCGTGTTCAGTCAGACTATGCGCGCA
GACACGATAGTCTAGTTGTTCTGGTCCATGAA
Probe-rpoB-516G-T/G-C P-CCATGAATTGGCTCAGCTGGGATCATGCTTCTTCGGTGCCCATCCTACTAGTTGCACGCTGTTCCGCGCA
GACACGATAGTCTACAGCGGGTTGTTCTGGM
Probe-rpoB-526-G/T/A-AC P-GGTCAACCCCGACAGCGGGATCATGCTTCTTCGGTGCCCATTGACCGTGCTATGAATGCATCGCGCAGA
CACGATAGTCTAACAGTCGGCGCTTGTH
Probe-rpoB-526- C-T/C/G-C P-GGGTCAACCCCGACAGCGGATCATGCTTCTTCGGTGCCCATAACGACTCCAGGTTAGCCTAGCGCGCA
GACACGATAGTCTAGACAGTCGGCGCTTGV
Probe-rpoB-531-TTG P-ACAGTCGGCGCTTGTGGATCATGCTTCTTCGGTGCCCATCCTAGATCAGACGTTCCTGTCCGCGCAG
ACACGATAGTCTACCCAGCGCCA
Primer-1b ATGGGCACCGAAGAAGCA
Primer-2c CGCGCAGACACGATA
a p-, 5= phosphorylation.
b RCA primer-1 binds to the padlock probe, generating a long ssDNA.
c RCA primer-2 binds to the nascent ssDNA if their binding sites are available. Each bound reverse primer extends and displaces the downstream primers and their extended
products.
TABLE 2 Twelve targeted RRDR mutations in rpoB genes of M. tuberculosis from 18 rifampin-resistant isolates and 59 clinical samples
Position Mutation Codon change Amino acid change
No. of isolates or samples
RCA Sequencing Phenotype (resistance)
Stored
isolate
Clinical
sample
Stored
isolate
clinical
sample
Stored
isolate
Recent clinical
isolate
514 TTC insertion TTC- TTCTTC Phe¡PhePhe 1 0 1 0 1 0
516 A¡T GAC¡GTC Asp¡Val 0 2 0 2 0 2
516 G¡T GAC¡TAC Asp¡Tyr 0 3 0 3 0 3
526 C¡A CAC¡AAC His¡Asn 0 5 0 5 0 5
526 C¡T CAC¡TAC His¡Tyr 2 4 2 4 2 4
526 C¡G CAC¡GAC His¡Asp 0 4 0 4 0 4
526 A¡T CAC¡CTC His¡Leu 1 3 1 3 1 3
526 A¡C CAC¡CCC His¡Pro 0 5 0 5 0 4
526 A¡G CAC¡CGC His¡Arg 1 7 1 7 1 7
531 C¡T TCG¡TTG Ser¡Leu 12 24 12 24 12 23
516 and 526 A¡T and A¡G GAC¡GTC and CAC¡CGC Asp¡Val and His¡Arg 0 2 0 2 0 2
511 and 516 T¡C and A¡G CTG¡CCG and GAC¡GGC Leu¡Ser and Asp¡Gly 1 0 1 0 1 0
NAa None None None NA NA NA NA NA 2
Total 18 59 18 59 18 59
a NA, not applicable.
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FIG 1 (A) RCA results monitored using Rotor-Gene 6000 real-time PCR machine. Using probe-rpoB-531-TTG as an example, specificity of the probe was
tested by targeting 1011 copies of 531-TTG template and 531 wild-type template with 1 pmol of the resistance mutation 531-TTG-specific probe. Ligation
of the probe to the standard templates was carried out using 1, 3, 5, 7, 10, and 15 cycles, followed by RCA reaction to amplify circularized padlock probe.
Specific probe signals were only detected with mutation-specific padlock probe targeting mutation template. Increasing the number of ligation cycles was
associated with earlier signal detection, as more circular molecules are generated. No signal was detected in the resistance-specific padlock probe targeting
wild-type template. Testing of other probes gives similar results. (B) Sensitivity testing of the probe-rpoB-531-TTG targeting 1011 copies of templates
containing various proportions of the 531-TTG target. Significant elevation of signal was detected in the presence of5% (5 109 copies) of the resistant
template, while in wild-type control, no signal was detected. (C) Standard testing with mixture of all mutation-specific probes in mutation detection.
Standard templates with resistance mutations at positions 511, 514, 516, 526, and 531, as well as the wild-type template, were ligated with the probe
mixture. After 15 cycles of ligation reaction, followed by RCA, positive signals were detected only in the templates containing resistance mutations while
wild-type template showed no signal. A weaker signal for two probes targeting mutation at residue 526 was observed and probably is the result of multiple
526 probes competing for the binding site.
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tion with 2-thiophene carboxylic acid (TCH) and paranitrobenzoic acid
(PNB) and by DST.
DST. All stored and new clinical isolates were tested for RIF suscepti-
bility on L-J slants by the absolute concentration method. Isolates were
determined to be resistant to RIF—at concentrations of either 50 g/ml
(low-level resistance) or 250 g/ml (high-level resistance)—if the inocu-
lum grew on one-quarter (1) of the slant surface or there were 20
colonies on slants containing the corresponding RIF concentrations, after
4 weeks incubation at 35 to 37°C (18).
DNA extraction. Scrapes of isolates grown on L-J slants were sus-
pended in 1 Tris-EDTA (TE), and DNA was extracted by using a stan-
dard phenol-chloroform procedure (19). DNA was extracted from clini-
cal specimens and purified using an optimized method, as described by
Leung et al. (20). Briefly, 2 ml of each decontaminated sputum specimen
was centrifuged at 5,000  g for 5 min, and 1 ml of the pellet was resus-
pended in 1 ml of TE in a 2-ml screw-cap microcentrifuge tube containing
200l of 1-mm glass beads (Sigma-Aldrich, St. Louis, MO). After vortex-
ing and centrifugation, the lysate was purified using in-house buffer with
Invitrogen Dynabeads MyOne Silane (Life Technologies Corporation,
Carlsbad, CA) magnetic beads. Briefly, binding buffer was prepared by
dissolving 120 g of guanidium thiocyanate in 100 ml of 0.1 M Tris-HCl
(pH 6.4). Subsequently, 22 ml of 0.2 M EDTA (pH 8.0) and 2.6 g of Triton
X-100 were added to the solution. A wash buffer was prepared by com-
bining 55 ml of ethanol and 45 ml of solution containing 3 M guanidium
thiocyanate, 10 mM Tris-HCl, and 10 mM NaCl (pH 8.0).
PCR amplification and sequencing of rpoB region. PCR was used to
amplify a 758-bp fragment of M. tuberculosis rpoB (which included the
RRDR), using the primers 5=-TGGTCCGCTTGCACGAGGGTCAGA-3=
(forward) and 5=-CAGGAAGGGAATCATCGCGG-3= (reverse) designed
for the present study. The reaction was performed in a final volume of 25
l containing 0.5 l of both forward and reverse primers (30 M), 2.5 l
of 10PCR buffer (including 1.5 mM MgCl2), 0.75l of deoxynucleoside
triphosphates (dNTPs; 2.5 mM each of dNTP), 1 U of Qiagen Hotstart
Taq polymerase, and 1 l of purified DNA. The reaction was performed
for isolates and clinical specimens under the following conditions: initial
denaturation at 95°C for 15 min, followed by 40 cycles at 95°C for 30 s,
65°C for 30 s, and 72°C for 1 min, and a final elongation at 72°C for 10
min. To identify possible contamination or inhibition, appropriate nega-
tive (no-DNA) and positive (H37Rv DNA) controls were used in each
step. For all clinical samples, a pair of M. tuberculosis-specific primer was
designed to determine the presence of M. tuberculosis (data not shown
here). PCR products were purified using a Millipore PCR purification
plate (Millipore, Billerica, MA) and sequenced using the ABI Prism
BigDye Terminator V3.1 ready reaction cycle sequencing kit (Applied
Biosystems, Foster City, CA) on an ABI 377 automated sequencer. Mul-
tiple sequences derived from each patient were analyzed using Sequencher
3.11 software (Gene Codes Corp., Ann Arbor, MI). Chromatograms de-
rived from both forward and reverse primers were aligned with the refer-
ence strain and carefully examined at the locations where resistance mu-
tations have been reported.
Padlock probe design. The padlock probes designed for the present
study were based on 12 known rpoB mutations at positions 511, 514, 516,
526, and 531 in the RRDR of RIF-resistant M. tuberculosis, as previously
described (3, 21).
Due to the polymorphism of mutations in these locations, ambiguous
positions or multiple probes were introduced. To ensure the efficiency of
padlock probe binding, the padlock probes were designed with minimum
secondary structure and with theTm of the 5= end probe binding arm close
to or above the ligation temperature (65°C). To increase the discrimina-
tory specificity, the 3= end binding arm was designed with a Tm 10 to 15°C
below ligation temperature. The genetic linker region between the two
binding arms was also carefully designed to minimize any similarities to
potentially cross-reacting sequences, after a BLAST search. In addition,
the primers used to amplify padlock probe signals, during RCA, were
designed specifically to bind to the linker regions with aTm of about 55°C.
The relevant primers and probes are given in Table 1, and the individual
mutations targeted are presented in Table 2.
Preparation of standard templates. To validate the sensitivity and
specificity of padlock probes, PCR products from isolates (previously am-
plified from isolates and sequence, as described above), containing wild-
type sequence and resistance mutations at one or more of positions 511,
514, 516, 526, and 531 were cloned into pGEM-T Easy vector system
(Promega, Madison, WI) according to the manufacturer’s protocol. Pos-
itive clones were resequenced to confirm the presence of the expected
mutations, and plasmid DNA was further amplified to generate linear
products, followed by purification using a Millipore PCR purification
FIG 1 continued
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plate, to serve as standard template controls. DNA copy numbers of stan-
dard templates were estimated using a DNA calculator (http://cels.uri.edu
/gsc/cndna.html); 1011 copies of standard DNA templates were used for
testing the specificity of the system.
Probe ligation, exonucleolysis, and signal amplification by hyper-
branched RCA. Ligation of padlock probes to templates was carried out
by mixing 1011 copies of each template with 1 pmol of the corresponding
individual padlock probe, 2 U of Pfu DNA ligase in 20 mM Tris-HCl (pH
7.5), 20 mM KCl, 10 mM MgCl2, 0.1% igepal, 0.01 mM rATP, and 1 mM
dithiothreitol in a total reaction volume of 10 l. Multiple-cycle ligation
was conducted to validate the specificity of each probe in recognizing its
corresponding template (see below). The reaction conditions included
one cycle of 5 min at 94°C to denature the template DNA, followed by 1 to
15 cycles of 94°C for 30 s and a 4-min ligation at 65°C. The ligation
mixture was then subjected to exonucleolysis to remove unreacted pad-
lock probe and PCR product in order to reduce subsequent ligation-in-
dependent amplification events. The exonuclease treatment was per-
formed in a 20-l volume by adding 10 U each of exonucleases I and III
(New England BioLabs, Ipswich, MA) to the ligation mixture and incu-
bating at 37°C for 30 min, followed by 94°C for 30 s to inactivate the
exonucleases.
The amplification of circularized padlock probes was performed in a
FIG 2 (A) Screening for resistance mutations by individual padlock probes in stored isolates. All 46 stored isolates were subjected to individual rpoB mutation-
specific padlock detection. A positive signal was detected only in the matched probe-template pairs. In comparison, samples showing the absence of particular
resistance mutations give no signal. (B) Using a mixture of mutation-specific probes to screen for mutations in stored isolates or clinical samples, positive signals
were detected in all samples containing resistance mutations while no signals were detected in samples showing the absence of resistance mutations. (C) Screening
for resistance mutations by individual padlock probes in clinical samples. All 78 clinical samples (a selection of which are shown here) were subjected to individual
drug resistance-specific padlock detection, and the positive signal was detected only in the matched probe and templates pairs. No signals were produced from
samples containing RIF-susceptible strains.
Chen et al.
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50-l volume by adding 8 U of Bst DNA polymerase (New England
BioLabs, Ipswich, MA), 5 l of reaction buffer, 400 M dNTP mix, 10
pmol of each RCA primer, 5% dimethyl sulfoxide (vol/vol), and 1 Sybr
green I (Sigma, St. Louis, MO) to the ligation mixture. The reaction was
carried out using a Rotor-Gene 6000 real-time PCR machine (Corbett
Research Pty, Ltd., Australia).
Determination of specificity and sensitivity of padlock probes and
RCA system. The specificity of padlock probes was determined by multi-
ple-cycle ligations of each probe with the corresponding resistance tem-
plate and the wild-type template to test their ability to distinguish them as
described above. Testing the sensitivity of each resistance-specific padlock
probe was carried out with a mixture of the resistance template with the
wild-type template in various proportions to a total of 1011 copies: 100%
(resistance template only), 50%, 10%, 5%, and 0% (wild-type only). The
ligation reaction was performed for 15 cycles, followed by RCA of probe
signal detection.
Testing the multiplex ability of padlock probes. The use of padlock
probes provides high multiplexing potential as cross-reactions between
probes in the ligation step does not affect signal detection. Interactions
between probes, if any, will only generate linear molecules that are easily
distinguished from the circularized probes arising from “correct” reac-
tions. To test the ability of multiplexed probes to detect any of the 12 target
FIG 2 continued
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mutations, all padlock probes were mixed together. Ligation of the pad-
lock probe mixture (1 pmol of each individual probe) with 1011 copies of
each individual resistance or wild-type template were carried out using
the reaction conditions described above, followed by RCA reactions to
amplify circularized probe signals.
Padlock probe and RCA detection of resistance mutations in iso-
lates and clinical samples.A total of 1011 copies of PCR amplicons of rpoB
region from isolates and 1010 to 1012 copies of PCR amplicons from clin-
ical samples were subjected to individual resistance-specific padlock
probe ligation or probe mixture ligation under conditions described
above, followed by exonucleolysis and RCA amplification of probe signal.
The signals were monitored on a Rotor-Gene 6000 real-time PCR ma-
chine.
RESULTS
DST. Phenotypic DST of isolates from 78 clinical specimens and
46 stored isolates revealed that 59 and 18, respectively, were RIF
resistant.
Sequencing of M. tuberculosis rpoB region. Sequencing of
the rpoB region from isolates and clinical samples revealed the
presence of RIF resistance mutations at multiple locations in
the RRDR (Table 2). Sixteen of eighteen RIF-resistant stored
isolates had single mutations at codons 526 or 531; one had two
mutations (at codons 511 and 516), and one, which was phe-
notypically RIF resistant, had the codon TTC inserted at posi-
tion 514. DNA from 59 of the 78 clinical samples displayed
single mutations at codon 516, 526, or 531 and two had muta-
tions at both 516 and 526 (Table 2).
Specificity and sensitivity of RCA. RCA of each circularized
probe showed that positive signals were only detected from reac-
tion mixtures containing the mutation-specific padlock probe
and corresponding resistance template; no signals were detected
from wild-type templates despite only single nucleotide differ-
ences compared to the resistance template (Fig. 1A). Increasing
the number of ligation cycles resulted in earlier detection and peak
of probe signal due to the increased number of circular probe
molecules (Fig. 1A).
After 15 ligation cycles, followed by RCA signal amplification,
positive signals were easily detected by probes, even when resis-
tance mutations represented only 5% of the total template tested
(Fig. 1B).
Specificity of multiplexed padlock probes. Each standard re-
sistance template and the wild-type template were ligated with the
mixture of all resistance-specific probes; after 15 cycles of each
ligation reaction followed by RCA, positive signals were detected
in all templates containing resistance mutations, while the wild-
type template showed no signal (Fig. 1C).
Detection of rpoBmutants in RRDR of isolate DNA. Screen-
ing of PCR amplicons from DNA extracts of all 46 stored clinical
isolates and H37Rv, with individual probes, clearly showed that pos-
itive signals were obtained only from RIF-resistant isolates containing
resistance mutations No signal was detected from PCR amplicons
derived from RIF-susceptible isolates. To increase the mutation de-
tection efficiency, all 47 samples were further subjected to ligation
reaction using a mixture of all mutation-specific probes. Positive sig-
nals were obtained only with isolates containing one or more of the
target mutations, as shown by sequencing; however, specific muta-
tions could not be identified by this approach. No signal was pro-
duced with susceptible (wild-type) isolates (Fig. 2B).
Detection of rpoB mutants in RRDR of clinical samples.
Screening of DNA extracts from all 78 clinical samples with indi-
vidual probes clearly showed a positive signal from 59 samples and
that no signals were produced from 19 patient-derived samples (a
selection of samples are shown in Fig. 2C).
Comparison of genotypic and phenotypic resistance result.
Both RCA detection and rpoB sequencing revealed the presence of
one or more mutations in 18 stored isolates and 59 clinical sam-
ples with 100% consistency. These results were consistent with
phenotypic DST of stored isolates. Of 78 clinical samples, 4
showed discrepant results between RCA/rpoB sequencing (geno-
typic results) and phenotypic DST of isolates: two samples with
rpoB mutations detected by both RCA and sequencing were phe-
notypically RIF susceptible and two, from which RIF-resistant
strains were isolated, had no rpoB mutations detected by either
RCA or sequencing. These discrepancies were confirmed on re-
peat testing.
In summary, RCA detected rpoB mutations in 57 of 59 clinical
samples (i.e., two “false-negative” results) from which phenotyp-
ically RIF-resistantM. tuberculosiswas isolated (96.6% sensitivity)
and in 2 of 19 samples (i.e., two “false-positive” results) from
which RIF-susceptible M. tuberculosis was isolated (89.5% speci-
ficity).
DISCUSSION
This study has shown that RCA using padlock probes can detect
resistance mutations in RIF-resistant M. tuberculosis isolates and
in template mixtures, including those in which resistance tem-
plates mutations are in a minority. This high level of sensitivity
allows direct testing on clinical specimens known to contain M.
tuberculosis, which reduces delay in introduction of appropriate
treatment and the risk of further resistance emerging. This assay
has the potential for quantitation, which would allow assessment
of the proportion of resistant organisms in the specimen and pro-
vide insight into the dynamics of emergent resistance. Impor-
tantly, the ease of performance, rapid turnaround, and multiplex
capacity indicate its potential for high-throughput routine screen-
ing of AFB-positive specimens or M. tuberculosis isolates, with
significant clinical benefits. Formation of the circular probe mol-
ecule, mediated by DNA ligase, confers very high allele discrimi-
natory ability (22, 23). As a result, the signal generated is highly
specific and easy to interpret, in contrast to many other probe-
based methods in which the result depends on a subjective assess-
ment of spot intensity.
The specificity of the mutant-specific padlock probes, individ-
ually and when multiplexed, has been evaluated by testing both
stored isolates and clinical samples. The fact that probe-probe
interactions cannot give rise to closed, circular molecules means
that large number of probes can be used in a single reaction tube to
recognize sequences of interest. This is particularly important for
the detection of rpoBmutants since multiple site substitutions can
contribute to RIF resistance. When additional mutations are dis-
covered, new probes can be easily designed and added to the panel
as required.
In the present study, we included 46 clinical isolates with
known RIF resistance, the standard strain (H37Rv, ATCC 27294)
and 78 culture-positive clinical samples to compare the accuracy
of mutation detection by PCR/sequencing and RCA using padlock
probes. The use of padlock probes and RCA provided genotypic
resistance data equivalent to that provided by rpoB amplification
and sequencing and, with few exceptions, phenotypic RIF suscep-
tibility testing. These results reinforced the utility of RCA, which
Chen et al.
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has also been applied, successfully, to the detection of INH resis-
tance in M. tuberculosis in our laboratory (24). The sensitivity
(96.6%) and specificity (89.5%) of RCA detection for clinical sam-
ples were comparable to those of a high-resolution melting anal-
ysis (HRMA) M. tuberculosis resistance detection method previ-
ously reported by our group (25) and support the suitability of the
technique for direct application of RCA detection to clinical sam-
ples.
False-positive results (rpoB mutations detected in specimens
from which isolates were RIF susceptible) may be related to the
threshold concentrations of RIF used for DST—which are based,
historically, on clinically achievable drug levels and experience
with response to therapy (18)—inhibiting growth despite low-
grade RIF resistance. Moreover, it is known that not all mutations
in RRDR confer phenotypic RIF resistance (26). Failure to identify
rpoB mutations in samples known to contain phenotypically RIF-
resistant M. tuberculosis is consistent with reports that up to 5% of
RIF-resistant strains contain rpoB mutations outside of the RRDR
(5) or are resistant due to other mechanisms, such as efflux pumps
(5, 27).
Engstrom et al. have recently described a similar approach to
detection of the most common rpoB mutations associated with
RIF resistance, using multiplexed padlock probes, including anM.
tuberculosis-specific probe and RCA (28). Our study has con-
firmed the utility of this approach and, in addition, has demon-
strated its potential for routine direct screening of clinical speci-
mens. Future studies that include samples other than sputum
(blood, cerebrospinal fluid, etc.) would further extend the clinical
applications of this technique in RIF resistance testing. Although
we did not include an M. tuberculosis-specific probe to confirm its
presence, all clinical specimens were positive for AFB on micro-
copy. Our intention was that RIF resistance testing would be used
selectively on AFB-positive specimens, since patients with a heavy
bacillary load are most infectious and most likely to fail therapy
and develop further resistance if not correctly treated initially.
Addition of an M. tuberculosis-specific probe and testing of all
specimens submitted for TB diagnosis would increase the cost
(depending on the prevalence of TB) but allow the diagnosis of TB
in patients with AFB-negative specimens. However, a multiplex
testing approach to detect M. tuberculosis and RIF resistance, si-
multaneously, remains an option, depending on setting, need, and
affordability. This would be particularly important in settings
where MDR-TB is common and/or cultures are not performed
routinely, where it could significantly improve TB control by op-
timizing treatment regimens, improving epidemiological surveil-
lance and contributing to understanding of the global spread and
transmission dynamics of MDR-TB.
The use of a commercial real-time PCR system, GeneXpert
MTB/RIF (Cepheid, Sunnyvale, CA), has been endorsed by the
World Health Organization and has allowed the rapid detection of
RIF resistance at the point of care, directly from untreated sputum
in less than 2 h with minimal hands on time. However, the cost of
the instrument and the consumables remain a financial burden for
patients in developing countries. Therefore, there is an urgent
need for a comparable method that can be performed in resource-
limited settings. RCA-based testing provides a result within 3 h,
and the end product could be simply detected by agarose gel elec-
trophoresis, which would eliminate the requirement for a real-
time PCR instrument. These simple requirements and easy data
interpretation make this method an attractive option.
We sought here to develop a simple, rapid, inexpensive, and
accessible method of RIF resistance detection for use in high-bur-
den, low-resource, and low-technology settings. Although the
number of cases considered in the present study was limited, our
findings do illustrate that the RCA assay could be utilized to
achieve high sensitivity and specificity in the direct detection of
rpoB mutation from clinical samples.
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